Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 + AK112 with or without chemotherapy in EGFR-mutant nonsquamous NSCLC after EGFR-TKI failure
CTR20222886Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Feb 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ambuzutinib, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Feb 2023; status: active.
02
Drugs
ambuzutinibivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222886.